肌动蛋白与创伤患者组织损伤相关,并在体外产生高凝状态
该研究在单中心I级创伤中心纳入108例创伤激活患者,采用血栓弹力图和靶向蛋白质组学检测肌动蛋白及其内源性抑制剂凝溶胶蛋白。与无严重组织损伤患者(新损伤严重度评分<15,n=10)相比,严重组织损伤患者(新损伤严重度评分>15,n=98)循环肌动蛋白水平更高(0.0428 vs. 0.0301,p=0.02);纤溶关闭患者凝溶胶蛋白水平呈降低趋势(0.1844 vs. 0.2052,p=0.17),组织型纤溶酶原激活剂抵抗患者亦呈降低趋势(0.1676 vs. 0.2188,p=0.06)。在10名健康志愿者的体外实验中,加入生理浓度的细胞骨架G-肌动蛋白使血栓弹力图角度从40.0°增至52.9°(p=0.002),并降低纤溶(达到最大振幅后30分钟的血凝块溶解百分比从4.0%降至1.6%,p=0.002),在3名志愿者中诱发纤溶关闭。作者认为肌动蛋白通过抑制纤溶酶的机制增加血凝块传播并诱发纤溶关闭,提示其在组织损伤相关纤溶关闭中起作用。
要点
- 严重组织损伤的创伤患者(新损伤严重度评分>15)循环肌动蛋白水平高于无严重组织损伤者(0.0428 vs. 0.0301,p=0.02)。
- 体外实验中,向健康志愿者全血加入生理浓度细胞骨架G-肌动蛋白使血栓弹力图角度从40.0°增至52.9°(p=0.002)。
- 体外加入肌动蛋白降低纤溶:达到最大振幅后30分钟的血凝块溶解百分比从4.0%降至1.6%(p=0.002),并在3名志愿者中诱发纤溶关闭。
- 纤溶关闭患者凝溶胶蛋白水平呈降低趋势(0.1844 vs. 0.2052,p=0.17),组织型纤溶酶原激活剂抵抗患者亦呈降低趋势(0.1676 vs. 0.2188,p=0.06),均未达统计学显著。
适用人群与场景
- 单中心I级创伤中心连续纳入的创伤激活患者108例,其中男性71%,中位年龄32.7岁,钝性机制66%,中位新损伤严重度评分41。
- 体外实验纳入健康志愿者10名(男性50%,中位年龄31.3岁)。
诊断标准与关键阈值
- 严重组织损伤定义为新损伤严重度评分>15(n=98),无严重组织损伤为新损伤严重度评分<15(n=10)。
研究设计与关键结果
- 研究类型为创伤患者蛋白质组学观察加健康志愿者体外实验,单中心,创伤患者108例、健康志愿者10名。
- 严重组织损伤患者(新损伤严重度评分>15,n=98)循环肌动蛋白水平高于无严重组织损伤者(新损伤严重度评分<15,n=10):0.0428 vs. 0.0301,p=0.02。
- 纤溶关闭患者凝溶胶蛋白水平呈降低趋势:0.1844 vs. 0.2052,p=0.17;组织型纤溶酶原激活剂抵抗患者凝溶胶蛋白水平亦呈降低趋势:0.1676 vs. 0.2188,p=0.06,均未达统计学显著。
- 体外实验中,加入生理浓度细胞骨架G-肌动蛋白使血栓弹力图角度从40.0°增至52.9°(p=0.002),达到最大振幅后30分钟的血凝块溶解百分比从4.0%降至1.6%(p=0.002),在3名志愿者中诱发纤溶关闭。
- 向对照血浆加入肌动蛋白后,显微镜监测显示纤维蛋白凝块纤维可溶解性降低,纤溶酶介导的纤溶减少。
证据类型、等级与局限
- 证据类型为单中心观察性研究加体外实验,原文未报告证据等级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为肌动蛋白通过抑制纤溶酶的机制增加血凝块传播并诱发纤溶关闭。
- 作者认为严重组织损伤的创伤患者存在高循环肌动蛋白水平,提示肌动蛋白在组织损伤背景下参与纤溶关闭。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: While tissue injury provokes fibrinolysis shutdown in trauma, the mechanism remains elusive. Cellular death causes release of structural proteins, including actin and myosin, which may interact with clot formation and structure. We hypothesized that tissue injury is associated with high circulating actin and that actin produces a hypercoagulable profile with decreased fibrinolysis in vitro.
METHODS: Blood was collected from trauma activation patients at a single Level I trauma center for thrombelastography and proteomics. Proteomic analyses were performed through targeted liquid chromatography coupled with mass spectrometry using isotope-labeled standards for quantification of actin and its endogenous inhibitor gelsolin. Based on the results, we added physiologic concentrations of cytoskeletal G-actin to whole blood from healthy volunteers and analyzed changes in thrombelastography, as well as to plasma and examined clot architecture using confocal microscopy of fluorescently labeled fibrinogen.
RESULTS: Overall, 108 trauma patients were included: majority (71%) men, median age of 32.7 years, 66% blunt mechanism, median New Injury Severity Score (NISS) of 41. Compared with patients without severe tissue injury (NISS < 15, n = 10), patients with severe tissue injury (NISS > 15, n = 98) had higher levels of circulating actin (0.0428 vs. 0.0301, p = 0.02). Further, there was a trend toward lower gelsolin levels in patients with fibrinolysis shutdown (0.1844 vs. 0.2052, p = 0.17) and tissue plasminogen activator resistance (0.1676 vs. 0.2188, p = 0.06).Ten healthy volunteers were included in the in vitro experiments (50% male; median age, 31.3 years). Actin significantly increased angle (40.0° to 52.9°, p = 0.002) and decreased fibrinolysis (percent clot lysis 30 minutes after reaching maximum amplitude, 4.0% to 1.6%; p = 0.002), provoking fibrinolytic shutdown in three patients. The addition of actin to control plasma decreased fiber resolvability of fibrin clots, monitored by microscopy, and decreased plasmin-mediated fibrinolysis.
CONCLUSION: Actin increases clot propagation and provokes fibrinolysis shutdown in vitro, through a mechanism of plasmin inhibition. High circulating levels of actin are present in trauma patients with severe tissue injury, suggesting actin contributes to fibrinolysis shutdown in the setting of tissue injury.
参考来源
- Coleman JR, Moore EE, Freeman K, et al. Actin is associated with tissue injury in trauma patients and produces a hypercoagulable profile in vitro. J Trauma Acute Care Surg. 2020. PMID: 32574484. doi:10.1097/TA.0000000000002739
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。